Market Place
Sourcing Support
FDA expunges all Ozempic, Wegovy doses from shortage list
02 Nov 2024 //
FIERCE PHARMA
Novo`s older obesity drug is safe and effective for children, study finds
11 Sep 2024 //
REUTERS
Novo Nordisk To Present New Diabetes And Obesity Data At EASD Meeting
06 Sep 2024 //
PR NEWSWIRE
Fake Ozempic: Batch Numbers Help Spread Dangerous Weight Loss Drugs
05 Sep 2024 //
REUTERS
Positive Interim Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
22 Aug 2024 //
BIOSPACE
Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
06 Aug 2024 //
GLOBENEWSWIRE
Teva launches generic version of Novo Nordisk`s diabetes drug Victoza
25 Jun 2024 //
REUTERS
Hikma Pharms Biologic Liraglutide Receives Tentative Approval in US
21 Jun 2024 //
FDA
Adalvo Receives European Approval for Liraglutide Pen
17 Jun 2024 //
PHARMABIZ
Adalvo Secures First EU Generic Approval for Liraglutide Pre-Filled Pen
13 Jun 2024 //
GLOBENEWSWIRE
4Moving Biotech Announces Positive Liraglutide Osteoarthritis Trial Results
10 Jun 2024 //
BUSINESSWIRE
AMRA Used To Evaluate Liraglutide Effect In Obesity
02 May 2024 //
BUSINESSWIRE
Biocon leads India`s push into anti-obesity drugs as patents lapse
08 Apr 2024 //
BUSINESS STANDARD
Biocon to obtain approval for diabetes drug, Liraglutide in UK
28 Mar 2024 //
INDINPHARMAPOST
UK probes GLP-1 drugs` potential suicide risks
27 Jul 2023 //
FIERCE PHARMA
Weight-loss drug shortage expands to Novo`s Saxenda
20 Jul 2023 //
FIERCE PHARMA
EU extends Ozempic review to include more weight-loss, diabetes drugs
13 Jul 2023 //
REUTERS
EU investigates Ozempic, weight-loss drug Saxenda after suicidal thoughts
11 Jul 2023 //
REUTERS
Sciwind to Highlight Positive Data for GLP-1 Peptide Agonist Ecnoglutide
23 Jun 2023 //
PR NEWSWIRE
Novo Nordisk`s Wegovy woes were an unexpected boon for Saxenda
04 Aug 2022 //
FIERCEPHARMA
Risk of patient overlap between Wegovy and Saxenda obesity drugs, Novo says
07 Jun 2021 //
REUTERS
Brazil cases dropping but relaxing health measures could reverse gains - PAHO
21 Apr 2021 //
REUTERS
Novo Nordisk’s Saxenda bags NICE recommendation
03 Nov 2020 //
PHARMATIMES
Novo Nordisk scraps Type 1 diabetes drug after phase 2 trial
31 Oct 2020 //
FIERCE BIOTECH
NICE recommends Novo Nordisk treatment for adults with obesity
30 Oct 2020 //
PHARMACEUTICAL-TECHNOLOGY
NICE recommends Novo`s liraglutide for management of obesity
30 Oct 2020 //
PHARMAFILE
Mylan challenge to Novo`s Victoza results in PTAB review
24 Jun 2020 //
FIERCE PHARMA
Novo Nordisk’s first semaglutide obesity trial hits the mark
13 May 2020 //
PMLIVE
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
01 Apr 2020 //
NEJM
Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents
31 Mar 2020 //
BUSINESSINSIDER
Saxenda`s appetite-cutting ability may inspire new obesity drugs
05 Mar 2020 //
FIERCE BIOTECH
NIHR to invest £59m in AMR, air pollution and infectious diseases
27 Jan 2020 //
PHARMA TIMES
NICE shuns Novo Nordisk`s obesity med Saxenda, citing CV questions
25 Jan 2020 //
FIERCE PHARMA
Novo drops oral GLP-1 analog to focus on next-gen Rybelsus
01 Nov 2019 //
FIERCE BIOTECH
Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes
19 Sep 2019 //
PHARMATIMES
Novo`s Ozempic tops Invokana, Victoza in double head-to-head win
18 Sep 2019 //
FIERCE PHARMA
Novo Nordisk reports positive data for oral semaglutide
18 Sep 2019 //
CLINEICALTRIALSARENA
Novo`s Ozempic tops Invokana, Victoza in double head-to-head win
18 Sep 2019 //
FIERCE PHARMA
Novo Nordisk rolls out authorized insulin generics
07 Sep 2019 //
FIERCEPHARMA
Novo Nordisk and Mylan Battle Over Generic Versions of Victoza
23 Aug 2019 //
BIOSPACE
Novo faces shareholder suit over insulin sales disclosures
16 Aug 2019 //
BIOPHARMADIVE
Novo`s Ozempic launch kicks into gear ahead of oral semaglutide FDA decision
10 Aug 2019 //
FIERCE PHARMA
AZ bags two extensions in latest CHMP decisions
01 Jul 2019 //
PHARMATIMES
Recent Ozempic, Victoza data ‘promising’ for diabetic kidney disease
27 Jun 2019 //
PHARMATIMES
FDA approves new treatment for pediatric patients with type 2 diabetes
19 Jun 2019 //
PR NEWSWIRE
Novo Nordisk`s oral semaglutide posts another heart safety win
12 Jun 2019 //
FIERCE PHARMA
Oral semaglutide showed superior reductions in blood sugar vs Jardiance
08 Jun 2019 //
PR NEWSWIRE
UPDATE 2-Novo Nordisk profit tops forecast as new diabetes drug shines
03 May 2019 //
CNBC
Novo Nordisk’s Victoza found to cut blood sugar in children
29 Apr 2019 //
PHARMA TIMES
Novo Nordisk files for EU approval of Ozempic in type II diabetes
26 Apr 2019 //
PHARMA TIMES
Novo Nordisk preps for speedy oral GLP-1 drug filing
01 Feb 2019 //
PM LIVE
Novo bets on swift FDA review for oral diabetes drug semaglutide
31 Jan 2019 //
ENDPTS
Novo Nordisk PIONEER 9 phase 3a study of oral semaglutide vs Victoza in Japanese
24 Nov 2018 //
PHARMABIZ
Korean wholesaler smuggled Novo’s obesity drug Saxenda into China
10 Nov 2018 //
FIERCE PHARMA
Lilly says diabetes drug Trulicity reduces heart risks in trial
06 Nov 2018 //
REUTERS
Novo Nordisk expands job cuts to 1,300 as exec`s play down Lilly’s GLP-1 threat
02 Nov 2018 //
FIERCE PHARMA
Novo Nordisk extends job losses, profit just misses forecasts
31 Oct 2018 //
REUTERS
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill
27 Oct 2018 //
FIERCE PHARMA
Eli Lilly picks up an oral GLP-1 diabetes drug from Roche sub for $50M
27 Sep 2018 //
ENDPTS
